Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.
The company's management team, including Chief Executive Officer Ben Zeskind and Chief Scientific Officer Brett Hall, will deliver a presentation on February 12 from 2:40 – 3:10 pm ET in Track 2. During the conference, they will discuss Immuneering's pipeline, platform, and business strategy.
The presentation will be accessible through a live webcast and will be archived in the Investor Relations section of Immuneering's website under Events & Presentations.
Immuneering (Nasdaq: IMRX), una società oncologica in fase clinica, ha annunciato la sua partecipazione alla 35a Conferenza Annuale sulle Scienze della Vita di Oppenheimer. La conferenza virtuale è programmata per l'11-12 febbraio 2025.
Il team dirigenziale dell'azienda, che comprende il Amministratore Delegato Ben Zeskind e il Direttore Scientifico Brett Hall, terrà una presentazione il 12 febbraio dalle 14:40 alle 15:10 ET nella Track 2. Durante la conferenza, discuteranno della pipeline, della piattaforma e della strategia aziendale di Immuneering.
La presentazione sarà accessibile tramite un webcast in diretta e sarà archiviata nella sezione Relazioni con gli Investitori del sito web di Immuneering sotto Eventi e Presentazioni.
Immuneering (Nasdaq: IMRX), una empresa de oncología en etapa clínica, ha anunciado su participación en la 35ª Conferencia Anual sobre Ciencias de la Salud de Oppenheimer. La conferencia virtual se llevará a cabo del 11 al 12 de febrero de 2025.
El equipo de gestión de la empresa, que incluye al Consejero Delegado Ben Zeskind y al Director Científico Brett Hall, realizará una presentación el 12 de febrero de 2:40 a 3:10 pm ET en la Pista 2. Durante la conferencia, discutirán el pipeline, la plataforma y la estrategia empresarial de Immuneering.
La presentación estará disponible a través de una transmisión en vivo y se archivará en la sección de Relaciones con Inversores del sitio web de Immuneering bajo Eventos y Presentaciones.
Immuneering (Nasdaq: IMRX)은 임상 단계의 종양학 회사로, Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 이 가상 컨퍼런스는 2025년 2월 11일부터 12일까지 예정되어 있습니다.
회사의 경영진, 즉 CEO Ben Zeskind와 CSO Brett Hall가 2월 12일 오후 2시 40분부터 3시 10분(ET)까지 Track 2에서 발표를 진행할 예정입니다. 컨퍼런스 동안, 그들은 Immuneering의 파이프라인, 플랫폼 및 비즈니스 전략에 대해 논의할 것입니다.
발표는 라이브 웹캐스트를 통해 접근 가능하며, Immuneering의 웹사이트 투자자 관계 섹션의 이벤트 및 프레젠테이션 아래에 보관될 것입니다.
Immuneering (Nasdaq: IMRX), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer. La conférence virtuelle est prévue du 11 au 12 février 2025.
L'équipe de direction de l'entreprise, comprenant le directeur général Ben Zeskind et le directeur scientifique Brett Hall, présentera le 12 février de 14h40 à 15h10 ET dans la Piste 2. Au cours de la conférence, ils discuteront de la pipeline, de la plateforme et de la stratégie commerciale d'Immuneering.
La présentation sera accessible via un webcast en direct et sera archivée dans la section Relations Investisseurs du site web d'Immuneering sous Événements et Présentations.
Immuneering (Nasdaq: IMRX), ein Unternehmen der Onkologie in der klinischen Phase, hat seine Teilnahme an der 35. jährlichen Healthcare Life Sciences Konferenz von Oppenheimer bekannt gegeben. Die virtuelle Konferenz ist für den 11. bis 12. Februar 2025 geplant.
Das Management-Team des Unternehmens, einschließlich CEO Ben Zeskind und CSO Brett Hall, wird am 12. Februar von 14:40 bis 15:10 Uhr ET in Track 2 eine Präsentation halten. Während der Konferenz werden sie über Immuneerings Pipeline, Plattform und Geschäftsstrategie sprechen.
Die Präsentation wird über einen Live-Stream zugänglich sein und im Bereich Investor Relations der Immuneering-Website unter Veranstaltungen & Präsentationen archiviert.
- None.
- None.
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering (IMRX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Immuneering's (IMRX) Oppenheimer conference presentation?
What topics will Immuneering (IMRX) discuss at the Oppenheimer Healthcare Conference?
Which Immuneering executives are participating in the Oppenheimer Healthcare Conference 2025?
